More than 150 participants took part in the Cooperation forum from Germany, France, Netherlands, Austria and Switzerland, such as Avestin, Bayer Pharma, BD Biosciences, BioFocus/Galapagos, Boehringer Ingelheim, Cfm Oskar Tropitzsch, Cisbio Bioassays, EMP Genetech, Exosome Diagnostics, Martin Bauer, Max Planck Innovation, Medicon, Notox, Patrys, Promega, Roche, R. P. Scherer, Sercona, Thermo Fisher Scientific, 4SC as well as scientific institutes from Germany.
The main topics included:
• Strategies of drug development in industry and academia
• Technology platforms for efficient drug research
• Compounds für novel therapies
The focus was set on drug development in oncology, cardiovascular diseases and infectious diseases.
Latest research results in oncogenomics, functional genomics and epigenetics as well as novel approaches for drug development were discussed. Cooperation models in drug discovery and translational research showed opportunities for collaboration of pharma, biotech, science and clinical research. The development of new compound classes, e.g. HDAC-inhibitors, anti-thrombic compounds or antibodies against bacterial infections was presented.
The forum receives comprehensive support by
the Bavarian State Ministry for Economic Affairs,
Infrastructure, Transport and Technology.
The Cooperation Forum is supported by: